Abstract
PRIMAGE is one of the largest research projects focusing on medical imaging, artificial intelligence (AI), and pediatric cancer treatment. This four-year European Commission-funded initiative involves 16 partners across Europe, including the European Society for Paediatric Oncology and major pediatric oncology units. The project establishes an observational in silico study using high-quality anonymized datasets—including imaging, clinical, molecular, and genetic data—to train and validate machine learning and multiscale algorithms. The resulting open cloud-based platform provides clinical assistance for diagnosis (phenotyping), treatment prediction, and prognosis. Initially validated on neuroblastoma and diffuse intrinsic pontine glioma, the platform is designed for future translation to other malignant solid tumors.
Introduction: Addressing the Data Gap in Pediatric Oncology
Pediatric cancers, particularly Neuroblastoma (NB) and Diffuse Intrinsic Pontine Glioma (DIPG), present significant challenges for clinical research. Due to their rarity, gathering sufficient data for robust clinical trials is difficult. While "big data" exists in the form of high-resolution imaging and genomic profiles, these datasets are often siloed and underutilized.
Clinicians currently lack integrated tools to synthesize these heterogeneous data types into precise, individualized predictions. There is a critical need for decision support systems (DSS) that can help determine whether a tumor will regress spontaneously or require aggressive intervention. PRIMAGE addresses this by creating a computational framework to bridge the gap between complex data and clinical action.
The PRIMAGE Technological Framework
The project is built upon a hybrid Cloud/High-Performance Computing (HPC) platform designed to handle massive datasets and complex simulations.
The architecture includes:
- PRIMAGE Core: Houses the simulation frameworks and models for diagnosis and tumor growth.
- Middleware: Connects the core to European clinical registries, biobanks, and cloud infrastructures like EOSC and EuroHPC.
- Web Platform: A user-centric interface for data upload, patient browsing, and visualization of results with confidence scores.
Multiscale Modeling and AI-Driven Insights
At the heart of PRIMAGE is a multiscale approach that links biological processes across three levels:
- Cell Scale: Modeling chemical and biological properties within a single cancer cell.
- Tissue Scale: Using agent-based models to track cell interactions and population dynamics.
- Tumor Scale: Simulating volume evolution and biomechanical interactions with surrounding tissues.
By treating medical images as "virtual biopsies," the platform uses radiomics and deep learning to extract quantitative biomarkers. These features are correlated with genomic profiles to provide a holistic, non-invasive view of the tumor.
Datasets and Clinical Validation
The project leverages extensive anonymized datasets from 16 European partners:
- Neuroblastoma (NB): Approximately 1,000 cases from the GPOH (German Society of Paediatric Oncology and Haematology) database.
- DIPG: Approximately 700 cases from the SIOPE (European Society for Paediatric Oncology) registry.
- Integrated Dataset: A target sample of ~900 cases featuring a complete mix of imaging (MRI, CT, PET), histology, and longitudinal clinical data.
The consortium has prioritized five critical clinical endpoints (CEPs) for validation, such as predicting spontaneous regression in low-risk NB and estimating survival periods for DIPG patients.
Conclusion and Future Directions
PRIMAGE represents a shift toward open science in oncology. By utilizing the European Open Science Cloud (EOSC), the project aims to provide a global resource for the scientific community. While data heterogeneity and the need for rigorous external validation remain challenges, the successful implementation of this platform for NB and DIPG will pave the way for its translation to other malignant solid tumors in both children and adults.
Summary updated